Preimplantation Genetic Screening (PGS)
Chromosomal abnormalities are one of the most common reasons for implantation failure and miscarriages that occur within the first 12 weeks of pregnancy. In fact, approximately 50-60% of miscarriages that occur in the first trimester are due to a fetal chromosomal abnormality. Chromosomally abnormal embryos may not differ in overall microscopic appearance from chromosomally normal embryos, making it difficult to identify which embryo(s) have the best chance of resulting in a healthy baby. By implanting a chromosomally normal embryo, the possibility of a successful implantation and pregnancy is significantly enhanced.
How is PGS Performed?
CombiMatrix utilizes a technique called Chromosomal Microarray Analysis (CMA) to evaluate the embryo for chromosomal abnormalities. By investigating hundreds of thousands of points along all 23 pairs of chromosomes, CMA is able to determine how many copies of any given region of a chromosome are present. PGS is designed to detect whole chromosome aneuploidy, which is the most common cause of failed implantation and/or early miscarriage. However, gains and losses of chromosomal segments larger than 20 Mb in size (segmental aneuploidy) may also be detected, and are anticipated to be associated with a similar risk.
Who Can Benefit From PGS?
In addition to increasing the likelihood of a successful pregnancy for any couple, PGS may of particular benefit to couples who:
- Have experienced one or more failed IVF cycles
- Have a history of recurrent miscarriage
- Prefer to have a single embryo transferred
- Have had a previous pregnancy or child with a chromosomal abnormality
- Are at increased risk for aneuploidy due to advanced maternal age
Click here for our PGS Patient Brochure